Table 1.
Demographic and clinical characteristics by exposure to fluoroquinolones (FQs)
| Characteristic | Any FQ exposure (n = 40) | No FQ exposure (n = 35) | P-value |
|---|---|---|---|
| Age (years) [median (IQR)] | 59 (41–79) | 56 (42–72) | 0.3 |
| Sex [n (%)] | 0.5 | ||
| Male | 23 (58) | 23 (66) | |
| Female | 17 (43) | 12 (34) | |
| Black or African–American race | 15 (38) | 8 (23) | 0.2 |
| Hispanic or Latino ethnicity | 0 (0) | 5 (14) | 0.01 |
| Birthplace | 0.4 | ||
| US born | 36 (90) | 29 (83) | |
| Foreign born | 4 (10) | 6 (17) | |
| HIV seropositive (among those tested for HIV) | 6/35 (17) | 3/32 (9) | 0.4 |
| Resistance to other drugs | |||
| Isoniazid | 0/38 (0) | 0/33 (0) | – |
| Rifampicin | 0/39 (0) | 0/33 (0) | – |
| Pyrazinamide | 0/30 (0) | 1/29 (3) | 0.3 |
| Ethambutol | 1/39 (3) | 1/33 (3) | 0.9 |
| Drug resistance to any of HRZE | 1 (2) | 2 (6) | 0.5 |
| MDR-TB | 0 (0) | 0 (0) | – |
IQR, interquartile range; HIV, human immunodeficiency virus; HRZE, isoniazid, rifampicin, pyrazinamide and ethambutol; MDR-TB, multidrug-resistant tuberculosis.